Rituximab Matches Leading MS Drug in Major Trial, New Research Finds

A phase 3 clinical trial published in the New England Journal of Medicine has found that rituximab performs as well as ocrelizumab at preventing new brain lesions in patients newly diagnosed with relapsing multiple sclerosis.

What the Trial Found

The New England Journal of Medicine has published results from the OVERLORD-MS trial, a phase 3 study comparing two drugs used to treat relapsing multiple sclerosis. The findings show rituximab was noninferior to ocrelizumab in preventing new or enlarging lesions detected on MRI scans.

Put simply: rituximab — a drug that has been around for decades and is used to treat several conditions including certain cancers and rheumatoid arthritis — held its own against ocrelizumab, a newer medicine licensed specifically for MS.

The Safety Picture

Both drugs carry risks, as all medicines do. But the trial found the rate of serious adverse events was similar across both treatment groups — meaning neither drug appeared considerably more dangerous than the other over the course of the study.

That matters. When doctors weigh up treatment options, safety profiles sit alongside effectiveness. A drug that works just as well and carries a comparable risk profile gives clinicians more choice.

Why Rituximab Is Worth Watching

Ocrelizumab, sold under the brand name Ocrevus, is a licensed MS treatment available on the NHS. Rituximab is older, available as a biosimilar — a near-identical copy of the original drug — and is generally cheaper to produce and prescribe.

If rituximab can match ocrelizumab’s performance, that could eventually have effect on NHS prescribing decisions and drug budgets. The NHS is under sustained financial pressure, and treatments that cost less but perform equally well attract attention from commissioners and clinicians alike. No formal NHS guidance change has been announced, and it would be premature to suggest one is imminent on the basis of a single trial. But the research adds weight to a body of evidence that has been building around rituximab’s use in MS.

Both drugs work by targeting B cells — a type of white blood cell thought to play a role in the immune system attacks that damage the nervous system in MS. Depleting these cells appears to reduce disease activity, as measured by MRI lesion counts.

What the Research Does Not Tell Us

MRI lesion activity is an important marker, but it is not the whole story in MS management. Long-term disability outcomes, patient quality of life, and real-world tolerability all matter too. The OVERLORD-MS trial results represent one piece of a larger puzzle, and neurologists will want to see how findings hold up over longer follow-up periods.

The tweet announcing the results was posted by the New England Journal of Medicine’s official account, @NEJM, one of the world’s most respected peer-reviewed medical journals.

—

Key Takeaways

• The OVERLORD-MS phase 3 trial found rituximab was noninferior to ocrelizumab in reducing new or enlarging MS lesions on MRI
• Serious adverse event rates were similar between the two treatment groups, according to the published results
• Rituximab is an older, biosimilar-available drug — findings could inform future NHS prescribing discussions, though no policy change has been announced

What This Means for Kent Residents

People living with relapsing MS in Kent should not change or query their treatment on the basis of this research alone — any questions about medication should go directly to your neurologist or MS specialist nurse, who can advise based on your individual circumstances. NHS Kent and Medway commissions a range of MS treatments, and decisions about which drugs are prescribed locally follow national NICE guidance. If you have concerns about your MS care, contact your GP in the first instance, or call NHS 111 for advice. The MS Society helpline is also available on 0808 800 8000 for anyone wanting to talk through what new research means for them.